
Australia’s nuclear imaging agents market to hit $30m by 2036
Its growth is driven by a rise in prostate cancer cases.
Australia’s nuclear imaging agents market is projected to reach $30m by 2036, according to a GlobalData report.
The sector’s expansion is attributed to the increasing incidence of prostate cancer and a shift towards precision diagnostics.
Australia accounted for approximately 15% of the Asia-Pacific market in 2024.
The increased uptake of agents like prostate-specific membrane antigen (PSMA) PET is also contributing to market growth.
“Historically, detecting prostate cancer has been challenging due to the limitations in conventional imaging,” said Shagufta Hasan, Medical Devices Analyst at GlobalData.